Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant bacterial infections, announced that CEO Dr. Deborah Birx will present at the 5th Annual Phage Futures Annual Meeting in Boston, MA. The presentation is scheduled for 1:15pm ET on November 19th, 2024.
Armata Pharmaceuticals (NYSE American: ARMP), una compagnia di biotecnologie in fase clinica specializzata in terapie a base di batteriofagi per le infezioni batteriche resistenti agli antibiotici, ha annunciato che il CEO Dr. Deborah Birx presenterà al 5° Annuale Incontro sui Fagi a Boston, MA. La presentazione è programmata per le 13:15 ET del 19 novembre 2024.
Armata Pharmaceuticals (NYSE American: ARMP), una empresa de biotecnología en etapa clínica especializada en terapias con bacteriófagos para infecciones bacterianas resistentes a los antibióticos, anunció que la CEO Dra. Deborah Birx presentará en la 5ª Reunión Anual sobre Fagos en Boston, MA. La presentación está programada para la 1:15 p.m. ET del 19 de noviembre de 2024.
Armata Pharmaceuticals (NYSE American: ARMP), 항생제 내성 박테리아 감염을 위한 박테리오파지 치료를 전문으로 하는 임상 단계의 생명과학 회사가 CEO 드보라 버크 박사가 매사추세주 보스턴에서 열리는 제5회 연례 파지 미래 회의에서 발표할 것이라고 발표했습니다. 발표는 2024년 11월 19일 동부 표준시 기준 오후 1시 15분으로 예정되어 있습니다.
Armata Pharmaceuticals (NYSE American: ARMP), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies par bactériophages pour les infections bactériennes résistantes aux antibiotiques, a annoncé que la PDG Dr. Deborah Birx fera une présentation lors de la 5ème Réunion Annuelle sur les Phages à Boston, MA. La présentation est prévue pour 13h15 ET le 19 novembre 2024.
Armata Pharmaceuticals (NYSE American: ARMP), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Bakteriophag-Therapeutika für antibiotikaresistente bakterielle Infektionen spezialisiert hat, gab bekannt, dass CEO Dr. Deborah Birx auf dem 5. jährlichen Phagen-Zukunfts-Meeting in Boston, MA, präsentieren wird. Die Präsentation ist für den 19. November 2024 um 13:15 Uhr ET angesetzt.
- None.
- None.
For more information: https://phagefuturesusa.com/events/phage-futures-2024
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-that-ceo-dr-deborah-birx-will-deliver-a-presentation-at-the-5th-annual-phage-futures-annual-meeting-302309391.html
SOURCE Armata Pharmaceuticals, Inc.
FAQ
When is Dr. Deborah Birx presenting at the Phage Futures Annual Meeting for ARMP?
What is Armata Pharmaceuticals (ARMP) main focus?
Where is the 5th Annual Phage Futures Meeting for ARMP being held?
